Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.
SRPT - Sarepta Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.60
DETAILS
HIGH:
$27.00
LOW:
$17.00
MEDIAN:
$20.00
CONSENSUS:
$21.60
UPSIDE:
21.01%
Stock News
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. A.
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright
Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report)'s stock had its "sell" rating reissued by HC Wainwright in a research report issued on Monday, MarketBeat.com reports. They currently have a $5.00 target price on the biotechnology company's stock. HC Wainwright's target price points to a potential downside of 71.43% from the stock's previous close. A number
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy. In ambulatory patients treated at ages 8 to 12, an age range in which functional decline becomes even m.
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta'.
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas. Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvov.
Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT
Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,026 shares of the biotechnology company's stock after selling 48,276 shares during the
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Sc
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular dystrop.
Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT)
Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares Alector and Sarepta Therapeutics' net
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Sarepta Therapeutics Investigation Initiated: Kahn Swick and Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRP
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Canada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPT
Canada Pension Plan Investment Board purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 70,800 shares of the biotechnology company's stock, valued at approximately $1,272,000. Canada Pension Plan
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be archived there f.
Price Targets
Sarepta price target lowered to $17 from $19 at RBC Capital
$17.00
(was $17.43)
RBC Capital
Morgan Stanley says Sarepta's CEO transition brings clarity ahead of catalysts
$25.00
(was $16.28)
Morgan Stanley
Sarepta price target lowered to $20 from $23 at Piper Sandler
$20.00
(was $20.21)
Piper Sandler
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
$27.00
(was $20.21)
Wolfe Research
Sarepta price target lowered to $19 from $20 at Evercore ISI
$19.00
(was $18.20)
Evercore ISI
Deutsche ups Sarepta target, says 35% stock rally overdone
$14.00
(was $21.68)
Deutsche Bank
Sarepta price target raised to $35 from $29 at Wedbush
$35.00
(was $21.68)
Wedbush
Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho
$31.00
(was $17.04)
Uy Ear
·
Mizuho Securities
Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets
$25.00
(was $15.87)
Ilya Zubkov
·
Loop Capital Markets
Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
$30.00
(was $15.98)
Andrew Tsai
·
Jefferies
Sarepta price target raised to $22 from $15 at Baird
$22.00
(was $22.80)
Robert W. Baird
Wedbush bullish on Sarepta, initiates with an Outperform
$32.00
(was $21.86)
Wedbush
Sarepta price target raised to $20 from $18 at Bernstein
$20.00
(was $18.91)
Bernstein
Sarepta price target lowered to $20 from $22 at Barclays
$20.00
(was $16.20)
Barclays
Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform
$26.00
(was $16.20)
Uy Ear
·
Mizuho Securities
Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird
$15.00
(was $24.45)
Brian Skorney
·
Robert W. Baird
Sarepta price target raised to $16 from $15 at Piper Sandler
$16.00
(was $23.45)
Biren Amin
·
Piper Sandler
Sarepta price target raised to $15 from $12 at Leerink
$15.00
(was $17.57)
Joseph Schwartz
·
Leerink Partners
Sarepta debt refinancing eases liquidity concerns, says Barclays
$22.00
(was $20.06)
Barclays
Sarepta price target raised to $12 from $6 at Deutsche Bank
$12.00
(was $20.30)
David Hoang
·
Deutsche Bank